Clinical trial
Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory…
NCT00051701 · Genzyme, a Sanofi Company, Industry · Terminated
Key facts
| NCT number | NCT00051701 |
|---|---|
| Title | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma |
| Official title | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkins Lymphoma |
| Intervention type | Drug |
| Interventions | alemtuzumab |
| Enrollment | 61 |
| Start date | Dec 1, 2002 |
| Completion | Aug 1, 2005 |
| First posted | Jan 17, 2003 |
| Last update posted | Mar 5, 2015 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: